Zollinger‑Ellison‑type Gastric Hyperacidity
Overview
Zollinger‑Ellison‑type gastric hyperacidity refers to the excessive production of gastric acid that occurs in Zollinger‑Ellison syndrome (ZES). ZES is a rare neuroendocrine disorder caused by gastrin‑producing tumors (gastrinomas) that stimulate the stomach’s parietal cells to secrete large amounts of hydrochloric acid. The result is severe, treatment‑resistant peptic ulcer disease and a high risk of complications such as ulcer perforation or bleeding.
- Who it affects: Most patients are adults 30‑60 years old, with a slight male predominance (≈55 %). About 25 % of cases occur in the context of multiple endocrine neoplasia type 1 (MEN‑1), a hereditary condition.
- Prevalence: ZES is estimated at 1–3 cases per million people per year worldwide, making it one of the rarest causes of gastric hyperacidity.[1]
Symptoms
Because the primary problem is over‑production of acid, symptoms are often related to ulcer disease and the effects of acid on the gastrointestinal (GI) tract.
- Abdominal pain – Typically epigastric, burning, and may improve with antacids but often recurs.
- Chronic diarrhea – Acid inactivates pancreatic enzymes and damages the intestinal mucosa, leading to malabsorption.
- Refractory peptic ulcers – Ulcers in the duodenum or jejunum that do not heal with standard therapy.
- Gastroesophageal reflux disease (GERD) – Heartburn, regurgitation, or sour taste.
- Gastrointestinal bleeding – Hematemesis or melena from ulcer erosion.
- Weight loss – Due to chronic diarrhea, malabsorption, and reduced appetite.
- Nausea and vomiting – May be caused by ulcer perforation or gastroduodenal obstruction.
- Severe acid‑related dental erosion – Rare but reported with chronic high acid exposure.
- MEN‑1 related symptoms – Hyperparathyroidism (bone pain, kidney stones) or pituitary tumors (headaches, vision changes) when ZES occurs as part of MEN‑1.
Causes and Risk Factors
Underlying cause
Zollinger‑Ellison syndrome is caused by gastrinomas, which are usually malignant neuroendocrine tumors located in the pancreas (≈60 %) or duodenum (≈30 %). These tumors secrete gastrin independent of normal feedback mechanisms, driving parietal cells to produce up to 10‑fold more acid.
Risk factors
- Multiple endocrine neoplasia type 1 (MEN‑1) – Inherited mutation in the MEN1 gene; accounts for ~25 % of ZES cases.
- Family history of gastrinoma – Rare, but autosomal‑dominant patterns have been described.
- Age & gender – Most cases diagnosed between 30–60 years; slight male predominance.
- Smoking – Increases risk of neuroendocrine tumors, though evidence is limited.
- Chronic atrophic gastritis or H. pylori infection – May coexist, but they are not causative for ZES.
Diagnosis
Diagnosing ZES requires confirming both the presence of a gastrin‑secreting tumor and the resultant hyperacidity.
Biochemical testing
- Fasting serum gastrin level – A level > 1000 pg/mL is highly suggestive; however, levels > 200 pg/mL with acidic gastric pH (< 2) are diagnostic.
- Secretin stimulation test – In ZES, gastrin paradoxically rises ≥ 120 pg/mL after IV secretin.
- Gastric pH measurement – pH < 2 confirms hyperacidity.
Imaging studies
- Multiphasic contrast CT scan – Detects primary tumor and hepatic metastases.
- Endoscopic ultrasound (EUS) – High sensitivity for small pancreatic or duodenal lesions.
- Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – Preferred for locating occult gastrinomas and assessing metastasis.
- Upper endoscopy (EGD) – Visualizes multiple duodenal ulcers and can obtain biopsies to rule out malignancy.
Other evaluations
- Baseline labs: CBC, electrolytes, kidney and liver function, calcium and parathyroid hormone (if MEN‑1 suspected).
- Genetic testing for MEN1 mutation if family history or additional endocrine tumors are present.
Treatment Options
Therapy is two‑pronged: control acid hypersecretion and treat the gastrinoma.
Acid‑suppression medications
- Proton pump inhibitors (PPIs) – High‑dose esomeprazole 80 mg twice daily or equivalent is first‑line. PPIs can reduce gastric acidity by > 90 % and promote ulcer healing.
- Histamine‑2 receptor antagonists (H2RAs) – Used when PPIs are intolerable; less effective for extreme acid output.
Definitive tumor management
- Surgical resection – Preferred for localized gastrinomas (< 2 cm) without metastasis. Enucleation or pancreaticoduodenectomy may be required.
- Medical therapy for unresectable or metastatic disease
- Somatostatin analogues (octreotide, lanreotide) – Reduce gastrin secretion and may shrink tumors.
- Targeted therapy (everolimus, sunitinib) – Indicated for progressive neuroendocrine tumors.
- Chemotherapy (streptozocin‑based regimens) – Reserved for high‑grade or rapidly growing lesions.
- Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for somatostatin‑receptor positive metastases; improves progression‑free survival.
Lifestyle and supportive measures
- Avoid NSAIDs, aspirin, and alcohol – These aggravate ulcer formation.
- Small, frequent meals – Reduces gastric volume and acid exposure.
- Calcium and vitamin D supplementation – Important if malabsorption or MEN‑1 related hyperparathyroidism is present.
Living with Zollinger‑Ellison‑type Gastric Hyperacidity
Long‑term management is a collaboration between the patient, gastroenterologist, endocrinologist, and surgeon.
Daily management tips
- Medication adherence – Take PPIs exactly as prescribed; do not skip doses.
- Track symptoms – Keep a diary of pain, bowel habits, and any bleeding episodes to discuss at appointments.
- Nutrition –
- Choose low‑fat, low‑spice foods.
- Incorporate probiotic‑rich yogurts to aid gut health.
- Maintain adequate hydration, especially if diarrhea is frequent.
- Regular follow‑up imaging – Typically every 6–12 months to monitor tumor size.
- Screen for MEN‑1 manifestations – Annual calcium, PTH, and pituitary hormone tests if a MEN‑1 mutation is known.
- Vaccinations – Annual influenza and COVID‑19 vaccines; consider pneumococcal vaccine if chronic acid suppression places you at higher infection risk.
Psychosocial support
Living with a rare, potentially malignant condition can cause anxiety. Counseling, patient‑support groups (e.g., Neuroendocrine Tumor Support Group), and reliable online resources (NIH Rare Diseases portal) are valuable.
Prevention
Because gastrinomas are largely sporadic, primary prevention is limited. However, risk reduction strategies include:
- Avoid chronic tobacco use – Smoking is linked to neuroendocrine tumor development.
- Prompt evaluation of persistent ulcer symptoms – Early detection of ZES improves outcomes.
- Genetic counseling for families with MEN‑1 – Allows early testing and surveillance of at‑risk relatives.
Complications
If untreated or inadequately controlled, Zollinger‑Ellison‑type hyperacidity can lead to serious health problems:
- Recurrent or perforated peptic ulcers – Can cause peritonitis, requiring emergency surgery.
- Severe gastrointestinal bleeding – May lead to anemia or hypovolemic shock.
- Malabsorption and nutritional deficiencies – Chronic diarrhea impairs absorption of fat‑soluble vitamins (A, D, E, K) and minerals.
- Gastric carcinoid tumors – Chronic hypergastrinemia stimulates enterochromaffin‑like cell hyperplasia, which can evolve into carcinoid neoplasia.
- Metastatic gastrinoma – Liver, lymph nodes, or bone metastases worsen prognosis.
- MEN‑1 related cancers – Including parathyroid carcinoma and pituitary adenomas, which increase morbidity.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with medication.
- Vomiting blood (bright red or “coffee‑ground” appearance) or black, tarry stools.
- Signs of shock: rapid heartbeat, low blood pressure, dizziness, or fainting.
- High‑fever (> 38.5 °C/101 °F) accompanied by abdominal pain, suggesting perforation or infection.
- Sudden onset of difficulty breathing or chest pain, which could indicate a perforated ulcer causing diaphragmatic irritation.
References
- American College of Gastroenterology. “Zollinger‑Ellison Syndrome.” ACG Clinical Guideline, 2022.
- Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org/
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2021.
- World Health Organization. “Neuroendocrine Tumors – Classification and Management.” WHO Press, 2020.
- Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome).” 2022.
- J. L. Cadiot et al., “Outcomes of surgical management of gastrinomas,” *Annals of Surgery*, vol. 279, no. 4, 2023, pp. 754‑762.
- H. C. Smith et al., “Efficacy of high‑dose PPIs in ZES,” *Gastroenterology*, 2021; 160(5): 1701‑1709.